TrialNature medicine2026

Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.

Cissy Kityo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.